NOT FOR DISTRIBUTION
Header cover image

Market Cap

€40.0m

Last Updated

2021/05/16 19:45 UTC

Data Sources

Company Financials +

Executive Summary

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Genkyotex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GKTX is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GKTX's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

1.2%

GKTX

-2.5%

FR Biotechs

-0.2%

FR Market


1 Year Return

27.9%

GKTX

35.1%

FR Biotechs

48.4%

FR Market

Return vs Industry: GKTX underperformed the French Biotechs industry which returned 35.2% over the past year.

Return vs Market: GKTX underperformed the French Market which returned 48.5% over the past year.


Shareholder returns

GKTXIndustryMarket
7 Day1.2%-2.5%-0.2%
30 Day-1.0%-5.2%1.3%
90 Day-4.7%-17.1%9.7%
1 Year33.6%27.9%35.1%35.1%52.3%48.4%
3 Year-81.5%-82.5%-20.5%-20.5%26.1%15.2%
5 Yearn/a-48.4%-48.5%78.2%55.2%

Long-Term Price Volatility Vs. Market

How volatile is Genkyotex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genkyotex undervalued compared to its fair value and its price relative to the market?

12.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GKTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GKTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GKTX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: GKTX is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GKTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GKTX is overvalued based on its PB Ratio (12.5x) compared to the FR Biotechs industry average (4.3x).


Future Growth

How is Genkyotex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-51.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GKTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GKTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GKTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GKTX's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if GKTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GKTX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Genkyotex performed over the past 5 years?

21.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GKTX is currently unprofitable.

Growing Profit Margin: GKTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GKTX is unprofitable, but has reduced losses over the past 5 years at a rate of 21.6% per year.

Accelerating Growth: Unable to compare GKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: GKTX has a negative Return on Equity (-529.17%), as it is currently unprofitable.


Financial Health

How is Genkyotex's financial position?


Financial Position Analysis

Short Term Liabilities: GKTX's short term assets (€3.2M) exceed its short term liabilities (€2.5M).

Long Term Liabilities: GKTX's short term assets (€3.2M) exceed its long term liabilities (€1.0M).


Debt to Equity History and Analysis

Debt Level: GKTX is debt free.

Reducing Debt: GKTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GKTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GKTX has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.3% each year.


Dividend

What is Genkyotex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GKTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GKTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GKTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GKTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GKTX's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average board tenure


CEO

Elias Papatheodorou (51 yo)

5.67yrs

Tenure

€576,293

Compensation

Mr. Ilias Papatheodorou, also known as Elias, has been the Chief Executive Officer at Genkyotex SA since September 30, 2015 and as its Director since February 28, 2017. Mr. Papatheodorou served as Chief Bu...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Elias's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Elias's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: GKTX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.


Top Shareholders

Company Information

Genkyotex SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genkyotex SA
  • Ticker: GKTX
  • Exchange: ENXTPA
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €39.971m
  • Shares outstanding: 14.07m
  • Website: https://www.genkyotex.com

Number of Employees


Location

  • Genkyotex SA
  • 516 Rue Pierre et Marie Curie
  • Labège
  • Midi-Pyrénées
  • 31670
  • France

Listings


Biography

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes ampli...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/16 19:45
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.